Candida glabrata biofilms: How far have we come?

Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs...

Full description

Saved in:
Bibliographic Details
Published in:Journal of fungi (Basel) 2017-03, Vol.3 (1), p.11
Main Authors: Rodrigues, Célia Fortuna, Rodrigues, Maria Elisa Costa, Silva, Sónia Carina, Henriques, Mariana
Format: Article
Language:English
Subjects:
antifungal
Biofilm
Biofilms
Candida glabrata
Candida species
Candidiasis
Drug resistance
Fungi
Genomes
Health risk assessment
Hyphae
Infection
Infections
Morbidity
Mortality
Resistance
Review
Science & Technology
Surveillance
Virulence factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response and serious recurrent candidiasis, particularly biofilm formation ability. For their extraordinary organization, especially regarding the complex structure of the matrix, biofilms are very resistant to antifungal treatments. Thus, new approaches to the treatment of C. glabratas biofilms are emerging. In this article, the knowledge available on C. glabratas resistance will be highlighted, with a special focus on biofilms, as well as new therapeutic alternatives to control them. This work was supported by the Programa Operacional, Fatores de competitividade— COMPETE and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012, and PEst-OE/EQB/LA0023/2013, Célia F. Rodrigues’ SFRH/BD/93078/2013 PhD grant, Maria Elisa Rodrigues’ Grant SFRH/BD/93078/2013. The authors thank the Project “BioHealth—Biotechnology and Bioengineering approaches to improve Programa Operacional Regional do Norte (ON.2—O Novo Norte), QREN, FE
ISSN:2309-608X
2309-608X
DOI:10.3390/jof3010011